AstraZeneca is looking to bolster its cancer R&D portfolio with therapies that target RNA-modifying enzymes and other proteins involved in cancer. On Thursday the Cambridge, UK-based pharma giant announced it would pay Boston-area biotech Accent Therapeutics $55 million up front to gain access to its drug discovery know-how in RNA-modifying protein biology. The biology of … Continue reading “Accent, AstraZeneca Ink Cancer Drug Deal to Block RNA-Modifying Proteins”
Category: Boston
NodThera Adds $55M to Advance Drugs to Better Regulate Inflammation
Our immune systems are designed to monitor for signs of foreign molecules, and among the first responses to such signals of potential danger are the formation of structures called inflammasomes. But the innate immune system’s natural inflammatory reaction, a protective mechanism meant to tackle any impending infection or injury, may also cause damaging inflammation in … Continue reading “NodThera Adds $55M to Advance Drugs to Better Regulate Inflammation”
Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact
Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases, the partners are expanding their pact to bleeding disorders. The deal announced Monday covers the development of potential treatments for hemophilia, which stems from genetic mutations that lead to insufficient levels of blood clotting … Continue reading “Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact”
Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs
Forma Therapeutics has developed a pipeline of small molecules aimed at rare blood disorders and cancers, but it aims to advance two—investigational treatments for sickle cell disease and for advanced prostate cancer—and find partners for the rest of them. Now the Watertown, MA-based company is considering tapping the public markets to add enough funds to … Continue reading “Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs”
After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO
It’s been a busy week for Repare Therapeutics. On Tuesday, the cancer drug developer struck up an alliance with Bristol Myers Squibb (NYSE: [[ticker:BMY]]) that pays $65 million now and as much as $3 billion later, depending on the progress made in coming years. On Friday, Repare filed for an IPO that could bring in … Continue reading “After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO”
Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More
A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual version of the ASCO conference, the cancer field’s largest, kicks off, with oncologists and others tuning in from throughout the country and around the world to check out the latest in cancer … Continue reading “Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More”
Flagship Pioneering Taps Chouraqui as CEO-Partner, CEO of Cellarity
Flagship Pioneering has created a dual role as CEO-partner of the firm and CEO of Cellarity, one of its spinouts, and named Fabrice Chouraqui to the position. Chouraqui was most recently president of the US pharmaceuticals business for Novartis (NYSE: [[ticker:NVS]]), a role from which he stepped down last August. Previously he held other leadership … Continue reading “Flagship Pioneering Taps Chouraqui as CEO-Partner, CEO of Cellarity”
New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech
Xconomy Insight is excited to offer two special webinars to our community this June. Sponsored by Eurofins, registration is free to all. Applying Cell-based In Vitro Assays to Improve In Vitro Hepatotoxicity Assessment Challenges Date: Wednesday, June 10, 2020 Time: 9:00am PDT / 12:00pm EDT Duration: 1 hour Register today In this webinar, we will … Continue reading “New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech”
COVID-19 Sparks New Opportunities for Digital Health Companies
Clinicians and regulators are rethinking how healthcare is provided amid precautions prompted by COVID-19. In-person physician visits don’t fit within the physical distancing guidelines that are now the new normal. New technology presents alternatives. As a digital therapeutics startup, Akili Interactive finds itself thrust in the midst of these changes. The Boston company has developed … Continue reading “COVID-19 Sparks New Opportunities for Digital Health Companies”
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq
COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list of life science companies preparing to join the public markets. Gene therapy company Generation … Continue reading “Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq”
Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More
As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything resembling a pre-pandemic normal without a COVID-19 vaccine. Moderna (NASDAQ: [[ticker:MRNA]]) moved one step closer to filling that need with the release of preliminary Phase … Continue reading “Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More”
AMAG Pharma Sells Off Women’s Health Product in Planned Divestment
AMAG Pharmaceuticals wants out of the women’s health business—and now it’s halfway there. On Thursday the Waltham, MA-based biotech said it had found a buyer for prasterone (Intrarosa), a steroid designed to treat pain during intercourse associated with menopause, one of two commercialized drugs it has been shopping around. The buyer of the AMAG Pharma … Continue reading “AMAG Pharma Sells Off Women’s Health Product in Planned Divestment”
Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes
The FDA on Thursday approved a Sunovion Pharmaceuticals treatment for Parkinson’s disease, giving patients a new way to take an old drug. The Sunovion product, Kynmobi, is a formulation of apomorphine hydrochloride, a drug that treats “off” episodes experienced by Parkinson’s patients. These are times when the standard of care drug, levodopa, wears off and … Continue reading “Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes”
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
HotSpot Therapeutics set out two years ago to find new ways to address elusive disease targets. It now has molecules on the path to becoming potential medicines backed by a fresh $65 million. The Series B round of funding announced Thursday was led by SR One, the venture investment arm of GlaxoSmithKline (NYSE: [[ticker:GSK]]). The … Continue reading “HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic”
With $30M, Octant Launches Synthetic Bio Search for Multi-Target Drugs
Octant, a new drug discovery company, launched Wednesday with millions in backing from tech investors to push ahead plans to leverage advances in science and in tech—including genomics, synthetic biology, and big data computation—to map out the relationships between chemicals, drug receptors, and diseases. On Wednesday the Emeryville, CA-based startup announced it raised $30 million … Continue reading “With $30M, Octant Launches Synthetic Bio Search for Multi-Target Drugs”
Rallybio Lands $145M to Alter Course of FNAIT and More Rare Diseases
One of the risks to a newborn’s life comes from the mother’s immune system. It attacks the platelets of the fetus, depleting these blood-clotting cells and risking uncontrollable bleeding in the baby. Rallybio aims to develop the first FDA-approved treatment for this rare condition and the startup has raised $145 million to bring that drug, … Continue reading “Rallybio Lands $145M to Alter Course of FNAIT and More Rare Diseases”
Early COVID-19 Vaccine Data Sets Up Moderna for Next Stages of Testing
Moderna’s experimental COVID-19 vaccine is showing signs it can elicit antibodies at levels comparable to those found in the blood of dozens of patients who have recovered from the infectious disease, according to early results released Monday. The company is now preparing to quickly bring its vaccine candidate into the next stages of human testing. … Continue reading “Early COVID-19 Vaccine Data Sets Up Moderna for Next Stages of Testing”
Akcea Therapeutics Taps Michael Price as Its Chief Financial Officer
Akcea Therapeutics on Monday said it appointed Michael Price as its new chief financial officer. He takes over the role from former CFO Mike MacLean, who joined the Boston-based rare disease drug developer shortly after its initial public offering in 2017. Price was most recently CFO at another rare disease drug developer, Novelion Therapeutics, which … Continue reading “Akcea Therapeutics Taps Michael Price as Its Chief Financial Officer”
Deciphera Pharmaceuticals Wins Early FDA Nod for GI Cancer Treatment
Some patients with a deadly type of tumor that forms in the gastrointestinal tract don’t respond to existing targeted therapies. On Friday the FDA approved Deciphera Pharmaceuticals drug ripretinib (Qinlock), a new treatment intended for patients with a gastrointestinal stromal tumor (GIST) who have failed at least three previous treatments. Deciphera (NASDAQ: [[ticker:DCPH]]) said the … Continue reading “Deciphera Pharmaceuticals Wins Early FDA Nod for GI Cancer Treatment”
Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More
This was a disappointing week for at least two major drug makers. French firm Genfit reported a trial failure in an intensely competitive indication, and New York-based Bristol Myers Squibb encountered a delay when the FDA declined to review its experimental multiple myeloma treatment. Genfit (NASDAQ: [[ticker:GNFT]]) was developing a treatment for nonalcoholic steatohepatitis, or … Continue reading “Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More”
Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System
It may seem like an unlikely link but the body’s response to arthritis may hold answers for better cancer drugs, says Luis Voloch, chief technology officer of startup Immunai. Immune cells respond to both conditions, but in different ways. Insights into the response for one disease could inform the treatment of the other, he says. … Continue reading “Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System”
Artax Biopharma Names Joseph Lobacki as New Chief Executive Officer
Artax Biopharma has appointed Joseph Lobacki as its new chief executive officer. Lobacki’s prior experience includes roles at Sanofi Genzyme, Medivation, Verastem (NASDAQ: [[ticker:VSTM]]), and Micromet, which was later acquired by Amgen (NASDAQ: [[ticker:AMGN]]). He succeeds company co-founder Damia Tormo, who has served as Artax’s CEO since its 2013 founding. The company says Tormo will … Continue reading “Artax Biopharma Names Joseph Lobacki as New Chief Executive Officer”
QurAlis Hauls In $42M to Move New ALS Therapies Into Human Testing
Few drugs exist that treat amyotrophic lateral sclerosis, a progressive disease that kills the nerve cells that allow patients to initiate and control muscle movement. QurAlis, a Cambridge, MA-based startup, has an ambitious plan to develop a number of “precision” therapies for the disease based on forms of the condition identified by genetic mutation or … Continue reading “QurAlis Hauls In $42M to Move New ALS Therapies Into Human Testing”
Celsius Therapeutics Names Jeanne Magram Chief Scientific Officer
Celsisus Therapeutics has appointed Jeanne Magram to serve as the Cambridge, MA-based drug developer’s chief scientific officer. She was most recently the CSO of Quentis Therapeutics. Magram’s experience also includes positions at Northern Biologics, Pfizer (NYSE: [[ticker:PFE]]), Boehringer Ingelheim, OSI Pharmaceuticals, and Roche. Celsius is using single-cell genomics to develop new treatments for cancer and autoimmune … Continue reading “Celsius Therapeutics Names Jeanne Magram Chief Scientific Officer”
Join us this Wednesday for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
Learn how digital tech is accelerating medical breakthroughs by registering your team to attend Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health. While some content focuses on the Boston ecosystem, we’re confident the forum – and virtual networking – will be valuable to a national audience. The May 13, 2020 event will explore the … Continue reading “Join us this Wednesday for Xcelerating Life Sciences: Biopharma’s Future in Digital Health”
AMAG Pharma Cuts 140 Jobs Amid Restructuring, COVID-19 Disruptions
Disruption caused by the pandemic has intensified a round of planned layoffs at AMAG Pharmaceuticals, new CEO Scott Myers said Monday morning on his first earnings call with the company. The Waltham, MA-based firm said it would cut 140 positions, or about 30 percent of its workforce, as part of a restructuring plan announced in … Continue reading “AMAG Pharma Cuts 140 Jobs Amid Restructuring, COVID-19 Disruptions”
Dyno Debuts With Plan, Partnerships for Better Gene Therapy Vectors
Gene therapies deliver healthy genetic material to patients’ cells to replace a mutated, disease-causing variant. Dyno Therapeutics aims to create better delivery vehicles for those genes by using machine-learning tools to engineer new types of harmless viruses that are more effective and simpler to manufacture. The Cambridge, MA-based biotech emerged from stealth Monday having signed … Continue reading “Dyno Debuts With Plan, Partnerships for Better Gene Therapy Vectors”
Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug
[Updated, 5/11/2020, 10:03 a.m. See below.] Eli Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted cancer therapy to pass the regulatory bar and the first that addresses tumors characterized by aberrations in one particular gene. The gene in question, RET, produces … Continue reading “Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug”
Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More
Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that goal. Last October, Alexion (NASDAQ: [[ticker:ALXN]]) struck a $930 million deal to acquire Achillion Pharmaceuticals, a biotech whose lead drug complements the Boston company’s … Continue reading “Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More”
Gemini Therapeutics Names Ex-Achillion Exec Marc Uknis Chief Medical Officer
Gemini Therapeutics has appointed Marc Uknis to serve as its chief medical officer. Uknis was most recently a vice president at Achillion, which was acquired by Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]) last year. His experience also includes positions at ViroPharma and CSL Behring. Cambridge, MA-based Gemini launched in 2017 to develop treatments for age-related macular degeneration. … Continue reading “Gemini Therapeutics Names Ex-Achillion Exec Marc Uknis Chief Medical Officer”
Akcea Adds Vertex’s Carla Poulson as Chief Human Resources Officer
Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) appointed Carla Poulson as chief human resources officer. Poulson was most recently vice president, senior human resources business partner at Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]). Her prior experience includes roles at grocery retail group Ahold, Pepsi Bottling Group, and ExxonMobil (NYSE: [[ticker:XOM]]). Boston-based Akcea, a spinoff of Carlsbad, CA-based Ionis Pharmaceuticals (NASDAQ: … Continue reading “Akcea Adds Vertex’s Carla Poulson as Chief Human Resources Officer”
FogPharma Appoints Tony Gibney as Chief Financial, Business Officer
FogPharma on Thursday named Tony Gibney to the roles of chief financial officer and chief business officer. Gibney, who was an investment banker before transitioning into biotech, was most recently CBO at Achillion Pharmaceuticals, where he led the process that concluded in Achillion’s sale to Alexion, a deal that closed in January. Previously he held … Continue reading “FogPharma Appoints Tony Gibney as Chief Financial, Business Officer”
PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug
PTC Therapeutics has reached an agreement to acquire Censa Pharmaceuticals and its lead asset, an experimental metabolic disorder therapy that is now being prepared for a pivotal study. The deal, announced after the market close Wednesday, will bring South Plainfield, NJ-based PTC (NASDAQ: [[ticker:PTCT]]) another compound for its pipeline of rare disease drugs. Want more … Continue reading “PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug”
Ventus Launches With $60M to Shine Light on Innate Immune System Drugs
The innate immune system has become a hot area for drug development, and for good reason. As the body’s first line of defense, its function (or dysfunction) plays a role in many diseases. The problem, says Ventus Therapeutics CEO Marcelo Bigal, is that drug developers have been working in the dark. Scientists don’t know the … Continue reading “Ventus Launches With $60M to Shine Light on Innate Immune System Drugs”
Encouraging Signals for New Cancer Cell Therapy Strategies
Chimeric antigen receptor T-cell therapies have shown remarkable efficacy in leukemia and lymphoma patients who relapsed or were refractory to several prior treatments, but many challenges remain in the cancer cell therapy field. Strategies that may improve upon first-generation therapies were presented during the American Association for Cancer Research virtual meeting with encouraging early activity, … Continue reading “Encouraging Signals for New Cancer Cell Therapy Strategies”
Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola
Alexion Pharmaceuticals has agreed to buy Portola Pharmaceuticals in a $1.4 billion deal that brings it a first-in-class therapy for treating life-threatening bleeding. According to financial terms announced Tuesday, Boston-based Alexion (NASDAQ: [[ticker:ALXN]]) will pay $18 for each outstanding share of Portola (NASDAQ: [[ticker:PTLA]]). That price is a a nearly 132 percent premium to Monday’s … Continue reading “Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola”
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
The genetic mutations that cause epilepsy don’t stop there. Praxis Precision Medicines CEO Marcio Souza says research also links these genes to other neurological conditions. The biotech startup is turning that research into new neuro drugs and it’s coming out of stealth to share details about its science and its pipeline, which already has two … Continue reading “Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs”
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
Lyra Therapeutics, a biotech company developing a new way to treat your persistently runny nose, has raised $56 million in its public markets debut. Late Thursday, Lyra offered 3.5 million shares priced at $16 apiece, which was the high end of its projected $14 to $16 price range. Those shares are expected to begin trading … Continue reading “Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses”
Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More
Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat patients with COVID-19. National Institute of Allergy and Infectious Diseases (NIAID) head Anthony Fauci praised the drug after preliminary data released this week from a federally funded trial involving more than 1,000 … Continue reading “Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More”
Goldfinch Bio Adds Kyle Kuvalanka, Lori Rudolph-Owen to C-Suite
Goldfinch Bio has appointed Kyle Kuvalanka to serve as chief financial and chief operating officer. His experience includes positions at Syros Pharmaceuticals, Blueprint Medicines (NASDAQ: [[ticker:BPMC]]), and Takeda Pharmaceutical (NYSE: [[ticker:TAK]]). In other moves, Cambridge, MA-based Goldfinch promoted Lori Rudolph-Owen to chief development officer. She joined the company in 2018 as senior vice president of … Continue reading “Goldfinch Bio Adds Kyle Kuvalanka, Lori Rudolph-Owen to C-Suite”
Intellia Therapeutics Taps Semma’s Lebwohl as Chief Medical Officer
Intellia Therapeutics (NASDAQ: [[ticker:NTLA]]) has appointed David Lebwohl to serve as executive vice president and chief medical officer. He is joining the Cambridge, MA-based gene-editing therapies company from Semma Therapeutics, where he also held the chief medical officer position. Lebwohl’s prior experience includes positions at Novartis (NYSE: [[ticker:NVS]]) and Bristol Myers Squibb (NYSE: [[ticker:BMY]]). Intellia is … Continue reading “Intellia Therapeutics Taps Semma’s Lebwohl as Chief Medical Officer”
Adicet Aims to Advance CAR-T Therapies in Reverse Merger with resTORbio
Adicet Bio, a privately held preclinical biotech looking to move ahead its “off-the-shelf” CAR-T cell therapies, has struck a deal with struggling resTORbio to use its Nasdaq listing as a backdoor to the public markets. The companies on Wednesday announced an agreement to combine in a type of transaction sometimes referred to as a “reverse … Continue reading “Adicet Aims to Advance CAR-T Therapies in Reverse Merger with resTORbio”
Radius Health CEO Hoeiland Steps Down, Martin Named Successor
Radius Health (NASDAQ: [[ticker:RDUS]]) president and CEO Jesper Hoeiland has stepped down, the company announced Tuesday. In a statement, Hoeiland said that after nearly 25 years abroad, he and his wife decided to return to Denmark to be closer to family and friends. According to a securities filing, he will serve as a paid advisor … Continue reading “Radius Health CEO Hoeiland Steps Down, Martin Named Successor”
Forma Therapeutics Taps Ex-Seres Exec Cook as Chief Scientific Officer
Forma Therapeutics has appointed David Cook to serve as its senior vice president and chief scientific officer. Cook’s experience includes senior roles at Seres Therapeutics (NASDAQ: [[ticker:MCRB]]), the International AIDS Vaccine Initiative, Anza Therapeutics, and Cerus Corporation. Watertown, MA-based Forma develops drugs for rare blood diseases and cancers. The company’s most advanced program, olutasidenib, is … Continue reading “Forma Therapeutics Taps Ex-Seres Exec Cook as Chief Scientific Officer”
AMAG Pharma Appoints Rainier’s Myers to Succeed CEO William Heiden
AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]]) on Tuesday announced Scott Myers has been appointed its new CEO. Myers was most recently CEO of bladder cancer drug developer Rainier Therapeutics. Previously he served as CEO of Cascadian Therapeutics, which was acquired by Seattle Genetics (NASDAQ: [[ticker:SGEN]]) in 2018. He also spent time as CEO of medical device company … Continue reading “AMAG Pharma Appoints Rainier’s Myers to Succeed CEO William Heiden”
At Rome Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs
A new biotech, Rome Therapeutics, launched Monday with $50 million and a plan to develop novel drugs based on new insights into repeats in the non-coding stretches of the human genome. Rome’s debut pulls back the curtain on what Rosana Kapeller, the company’s co-founder and CEO, has been up to since she left Nimbus Therapeutics … Continue reading “At Rome Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs”
Xilio Taps Former Tesaro Exec Martin Huber as Chief Medical Officer
Xilio Therapeutics has appointed Martin Huber to serve as its chief medical officer, the same position he held at Tesaro before its 2018 acquisition by GlaxoSmithKline (NYSE: [[ticker:GSK]]). His experience also includes roles at Merck (NYSE: [[ticker:MRK]]), Schering-Plough, Roche, and Rhone-Poulenc Rorer. Waltham, MA-based Xilio is developing antibody cancer drugs designed to activate their cancer-killing … Continue reading “Xilio Taps Former Tesaro Exec Martin Huber as Chief Medical Officer”
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing signs of slowing down, at least when it comes to drugs filed for accelerated approval. The regulator signed off on three such drugs in the past week. These approvals are … Continue reading “Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More”
Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory
Affinivax has a lead program with early clinical data showing the potential to best a pharmaceutical giant’s blockbuster vaccine. The startup now has $120 million in financing to see just how much further its technology can go. The Series B round of funding announced Thursday was led by Viking Global Investors. Cambridge, MA-based Affinivax develops … Continue reading “Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory”
Biogen Pushes Finalized Filing for Alzheimer’s Drug to Third Quarter
Biogen last year said it would ask the FDA to review its potential Alzheimer’s disease treatment, aducanamab, sometime in “early” 2020. The submission is being made under a rolling review, in which sections of an application are filed as they are completed rather than all at once. Now the Cambridge, MA-based company says the regulatory … Continue reading “Biogen Pushes Finalized Filing for Alzheimer’s Drug to Third Quarter”